Skip to main content

Table 1 Patient characteristics (N = 80)

From: DNA polymeraseη protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy

characteristic No. of patients %
Age(yrs)   
   Median 54.0  
   Range 26.0-79.0  
Sex   
   Male 49 61.3
   Female 31 38.7
ECOG performance status   
   0 36 45.0
   1 42 52.5
   2 2 2.5
Primary sites   
   Cardia 21 26.3
   Body 18 22.5
   Antrum/pylorus 41 51.2
Metastatic sites   
   Liver 26 32.5
   Lung 21 26.3
   Peritoneum 19 23.8
   Others 14 17.4
Pathologic differentiation N0   
   G1 2 2.5
   G2 26 32.5
   G3 52 65.0
Treatment Response (1st line)   
   CR 2 2.5
   PR 36 45.0
   SD 24 30.0
   PD 18 22.5
2nd-line chemotherary regimen   
   BSC 57 71.3
   FOLFIRI 6 7.5
   XELIRI 8 10.0
   DX 6 7.5
   TP 3 3.7
  1. CR, complete response; PR, partial response; SD, stable disease; PD, progression disease;
  2. BSC, best supportive care; FOLFIRI, 5-fluracil plus leucovorin plus irinotecan; XELIRI, capecitabine plus irinotecan; DX, docitaxel plus capecitabine; TP, paclitaxel plus cisplatin.